(2) Luminal group (molecular profile characterized by expression of high levels of estrogen receptors and other molecules found in the luminal mammary epithelium).
(3) Basal group (expresses basal and ME molecules).
(4) HER-2 group (expresses high level of HER2 receptors).
It was found that each category has a characteristic behavior and outcome and differs considerably in their response to treatment lines; e.g. the first two groups are well responders to endocrine therapy in addition to a combination of radio-and chemotherapy. HER-2 group responds well to Herceptin (a molecular therapy) which is not effective in other groups. The basal group has aggressive behavior and patients do not respond to either radiotherapy or chemotherapy [4] .
Basal-like tumors express genes characteristic of basal/ME cells as high molecular-weight cytokeratins including CK5, CK14, and CK17 in addition to smooth muscle-specific markers, calponin, caldesmon, p63, beta-4 integrin, laminin, maspin, CD10, P-cadherin, caveolin-1, nerve growth factor receptor (NGFR) and S100 protein [5, 6] . In addition to structural roles, many of the basal-like gene products have been implicated in cellular proliferation, suppression of apoptosis, cell migration and/or invasion and all hallmarks of cancer [7, 8] . They underexpress ER, ER-responsive genes, and other genes characteristic of luminal epithelial cells of the normal mammary gland, as well as genes located in the HER2 amplicon on 17q21 [9] . Collectively, the gene-expression profile of basal-like tumors provides myriad candidate genes that might contribute to their aggressive phenotype and, arguably, may suggest a less differentiated "stem/progenitor" cell phenotype or a stem cell origin for these tumors [10] .
Basal-like carcinomas are usually of high histologic grade; 75% to 100% are grade 3 [11] [12] [13] [14] . Other important histologic features include pushing, noninfiltrative borders, large zones of geographic or comedo-type necrosis, stromal lymphocytic infiltrates, scant stromal content, lack of tubule formations, marked cellular pleomorphism, high nucleo-cytoplasmic ratios, vesicular chromatin, prominent nucleoli, high mitotic indices, and frequent apoptotic cells [10, 12] .
Basal-like carcinomas are also characterized by the presence of metaplastic elements, in the form of squamous and spindle cells, and glomeruloid microvascular proliferation [15] . Most studies have reported an association between basal-like carcinomas and both larger primary tumor size [11, 12] and lymph node negativity [12] [13] [14] 16] . However, other authors did not find such an association [13, 17] . Basal-like tumors may be associated with high-grade ductal carcinomas in situ (DCIS), which are usually solid, flat, or micropapillary types, and demonstrate the same immunoprofile as the invasive component [18] .
The aim of this study was identification of breast cancers with basal phenotype, correlation between the clinicopathologic characteristics of both basal and nonbasal phenotypes and correlation of the basal phenotype with the available clinical follow up data of patients aiming to find out how basal phenotype affect patients' outcomes.
Material and Methods:
Specimens of the study Formalin-fixed paraffin-embedded blocks of 168 female patients diagnosed as primary invasive breast carcinoma were obtained from the archives of the Surgical Pathology Laboratory, South Egypt Cancer Institute, Assiut University. All specimens included in this study were selected from 518 consecutive series of breast cancers referred to the lab between years 2008 and 2012. Three hundred and fifty cases were excluded because they were unsuitable for tissue microarray construction. Available data, including patient's age at diagnosis, tumor laterality, tumor size, lymph node status, pathological stage, operation type and histopathological diagnosis were obtained from the institute medical records.
A representative H&E., stained slides were reexamined for each specimen for detailed histopathological features including; tumor type (according to WHO classification, 2003) , grade (according to Elston and Ellis grade, 1991), tubular formation, nuclear pleomophism, mitotic index, LVI (positive, negative and questionable), presence of necrosis, presence of fibrotic foci, associated DCIS (percentage and types), state of tumor margin (pushing or infiltrative margin) and lymphocytic stromal infiltrate (mild, moderate or severe).
Tissue Microarrays (TMA) and Immunohistochemistry (IHC)
A mark was made using permanent color pen on the slide at the site of invasive duct carcinoma. Paraffin blocks of the corresponding slides were also marked for the same sites, considered as donor blocks. As long as several blocks for each case were feasible, multiple sites from more than one block were marked. Manual tissue microarrays were constructed, using Array mold kit, TJ arrayer (supplied from IHC world online store, USA) with 1.5 mm stylet and 1.5 mm reusable rubber array mold used to construct paraffin block carrying 150 core holes.
Cores of spleen, salivary gland, thyroid and rectal mucosa were used in the corners as landmark for the block and slide. Three grids (groups) were constructed; each grid consists of two patches (TMA blocks). So, six TMA blocks were constructed, each block contained 88 cores with the four cores in the corners as landmark. One slide for each TMA block was stained with H&E as shown in figure 1. Sections of 5µm thickness from each TMA block were cut and mounted on positively charged slides. Antigen retrieval was done for all slides using the Dako PT link. Then endogenous peroxidase activity was blocked using hydrogen peroxide block for 10-15 minutes. Following protein block, slides were stained with antibodies against Ck14 and Ck5/6 using streptavidinbiotin immunoenzyme technique according to the lab vision kit protocol. CK14 was monoclonal antibody with a dilution of 1/100 (Catalog# RB-9020-P). CK 5/6 was monoclonal antibody with a dilution of 1/10 (Catalog# MS-187-P). Antibodies were applied for one hour at room temperature. All were obtained from the Thermo scientific company (46360 Fremont BLvd, USA). For the visualization of the antibody-enzyme complex, 3,3 diamino-benzidine-tetrahydrochloride (DAB) was used (Catalog # TP-015-HD); counterstaining was done with Myer's hematoxylin and examined by light microscopy. Positive and negative controls were used.
Evaluation of IHC data (Scoring)
Expression of CK14 and CK5/6 were assed using the modified histochemical score (H-score). This score combined an assessment of intensity of staining and percentage of positivity. Intensity was scored as 0, 1, 2, or 3 corresponding to negative, weak, moderate or strong positivity. In addition, the percentage of positive cells was ranged from 0-100. The final score ranged from 0 to 300 (intensity x percentage). Each core was scored individually and a mean of the informative cores was obtained for each tumor. If only one informative core (>50% of core with tumor) was obtained, the overall score applied was the absolute H-score. Membranous and cytoplasmic immunoreactivity were considered positive for keratins [19] . The H-score was interpreted as follows: ≤50= negative, 51-100= weakly positive, 101-200= moderately positive and >201-300= strongly positive [19] .
Statistical Analysis
The statistical software package SPSS version 21 was used for all analysis. The Chi-Square test was used to detect the significance of clinicopathological criteria of basal phenotype breast carcinoma in relation to the non-basal groups. Kaplan-Meier survival analysis and Log rank tests for overall survival (OS), disease-free interval (DFI) and distant metastasis-free interval (DMFI) were used to investigate the relation between basal phenotype and non-basal phenotypes with the patients' outcomes. DFI, OS and DMFI were defined as time from diagnosis to recurrence, death or occurrence of distant metastasis respectively, or end points at the conclusion of the follow-up period, using standardized definitions proposed by [20] . The median follow-up was 32 months (range 1-72 months). P values of < 0.05 were regarded as statistically significant.
Results:

Clinicopathological Findings
One hundred and sixty eight specimens of primary invasive breast carcinoma were studied in the current research. The age range of the studied patients was 27-85 years. Mean age was 52.27± 12.71 years with 68 patients (40.5%) below 50 years old and 100 patients (59.5%) above 50 years old. All of them were complaining of breast mass.
The tumor was unilateral in 134/168 cases (79.8%) and bilateral in six/168 cases (3.6%) and not-reported in 28/168 cases (16.6%).
The tumor size was ≤ 2cm in 26/168 cases (15.4%) and > 2cm in 142/168 cases (84%). There were 38 cases (22.5%) with no lymph node metastasis while 49 cases (29%) had metastasis in < 4 lymph nodes and 70 cases (41.4%) showed metastasis in ≥ 4 lymph nodes. PR was positive in 56 specimens (33.1%), negative in 79 specimens (46.7%) and not-reported in 33 specimens (19.5%). ER was positive in 73 specimens (43.2%), negative in 59 specimens (34.9%) and not-reported in 36 specimens (21.3%). One hundred and twenty nine cases (76.3%) were subjected to modified radical mastectomy (MRM), while 16 cases (9.5%) were subjected to conservative surgery and 17 cases (14.2%) were underwent other surgeries (simple mastectomy and excisional biopsy) ( (2003), most of the specimens, 142 (84.5%) were of invasive duct carcinoma, not-otherwise specified (IDC, NOS) type, two (1.2%) were IDC with squamous cell differentiation, one (0.6%) was IDC with mucoid differentiation, one (0.6%) was invasive papillary carcinoma, nine (5.4%) were invasive lobular carcinoma (ILC), eight (4.8%) were mixed IDC and ILC, one (0.6%) was mucinous carcinoma and one (0.6%) was squamous cell carcinoma. In situ component was found in 47 specimens (27.8%), of comedo, cribriform, clinging, papillary, solid and micropapillary patterns.
IDC (NOS) was graded from (1 to 3) according to Elston and Ellis grades (Elston and Ellis, 1991) with six cases (3.6%) were grade 1, 140 cases (83.3%) were grade 2 and 7 cases (4.2%) were grade 3. Lymphovascular invasion was present in 85 cases (50.3%), negative in 39 cases (23.1%) and questionable in 34 cases (20.1%).
Necrosis was present in 62 specimens (36.9%), fibrotic foci was present in 150 specimens (89.3%). Tumor margin was infiltrating in 162 specimens (96.4%) and pushing in six specimens (3.6%).
Immunohistochemistry:
Immunohistochemical assessment of the 168 invasive breast carcinomas revealed that, there were 77 cases (45.6%) were positive for CK5/6 and 81 cases (47.9%) were positive for CK14 (figure 2). Cut-off point (of H-score) was 50 where 50 and less was negative and more than 50 up to 300 were all positive. Accordingly, there were 81 cases (47.9%) with basal phenotype corresponding to 66 cases (39%) of the other types and 21 cases (13.1%) were missed. Table ( 2) shows that most of the cases (basal and non-basal) were above age 50 years (58% and 59.1% respectively). For size of the tumor, most of the cases (basal and non-basal) were of large size more than 2 cm (85.2% and 83.3% respectively).For grade of the tumor, most cases were of grade two (81.5% and 87.9% of the basal and non-basal, respectively). For lymph node (LN) metastasis; within the basal group, 19 cases (23.5%) had no LN metastasis, 26 cases (32.1%) had (1-3) LNs metastasis while 27 cases (33.3%) had four and more LNs metastasis and nine cases (11.1%) were not applicable. This was corresponding to 15 cases (22.8%) with no LN metastasis within the non-basal group, 17 cases (25.8%) with (1-3) LNs metastasis, 33 cases (50%) with four LNs and more and one case was not applicable. As regarding vascular invasion, most cases showed vascular invasion (42% and 62.1% of the basal and non-basal cases, respectively). For necrosis, 42% of basal group showed necrosis corresponding to 34.8% of non-basal group. 95.1% and 97% of the basal and nonbasal cases had infiltrative tumor margins, respectively. Most of the cases showed absence of DCIS (79% and 63.6% of the basal and non-basal groups respectively). As regarding CK14 expression, 53.1% of BLBCs cases were positive for expression of CK14, 24.7% of BLBCs cases were negative and 22.2% of BLBCs were missed. As regarding CK5/6 expression, 69.1% of BLBCs cases were positive for expression of CK5/6, 11.1% of BLBCs cases were negative and 19.8% of BLBCs were missed. As regarding CK19 expression, 42.2% of BLBCs cases were positive for expression of CK19, 16.7% of BLBCs cases were negative and 41.1% of BLBCs were missed. As regarding the follow up, the median follow-up was 32 months (range 1-72 months). Five patients (6.2%) with BLBCs experienced local recurrence versus two (3%) patients with NBLBCs. Seven patients (8.6%) with BLBCs died versus eight patients (12.1%) in NBLBCs. Fourteen cases of both basal and non-basal carcinomas experienced distant metastasis with percentages of 17.3% and 21.2%, respectively. (table 2) , it was noticed that there was significant association between the basal phenotype and presence of lymphovascular invasion (pvalue< 0.001), presence of necrosis (p-value< 0.001), infiltrative margin (p-value< 0.001), with inflammatory cellular stromal infiltrate (p-value= 0.006) and cytoplasmic expression of CK5/6 (p-value= 0.014).
Although the number of basal phenotype cases with larger tumor size was more than those of the non-basal group, there was no statistically significant association with larger size (p-value= 0.75). Also, no significant association was found between the basal phenotype with higher grade (p-value= 0.22), lymph node positivity or negativity (p-value= 0.27) or older age group (p-value= 0.89) and those of the non-basal group.
Survival Analysis:
Kaplan-Meier survival analysis and Log rank tests for OS, DFI and DMFI were used to investigate the relation between basal phenotype and non-basal phenotypes with the patient's outcomes as shown in table (3) and figure (3) which showed no statistical significance between the basal phenotype and OS, DFI or DMFI. 
Discussion:
The terminology, definition and classification of basal-like breast carcinomas are controversial and vary in the literature, making comparison of clinicopathologic features difficult [21] . Different terms are used to describe these tumors as 'basal-like', 'basal', 'Core Basal' and even 'basaloid', as well as those with a 'basal/ myoepithelial phenotype' [21] .
BLBC is characterized by expression of genes usually found in basal/ myoepithelial cells of the normal breast [15] . Although gene expression profiling is considered the ''gold standard'' method for identification of BLBC, this approach is not currently feasible for large-scale clinical applications or retrospective studies using formalin fixed, paraffinembedded samples. Therefore, as an alternative, expression of basal/myoepithelial cell proteins identified by immunohistochemical staining has been used as a surrogate of gene expression [22] . Some studies, including our own, have used basal cytokeratins (e.g., CK5/6 and CK14) alone to define BLBC [23, 24] regardless of the expression of other markers. Basal-like breast carcinoma represents a distinctive group of invasive breast carcinomas with specific genotype and immunoprofile. It is associated with poor prognosis and currently no targeted therapy is available [25] . There are limited numbers of studies investigating morphological features of BLBCs and to date, detailed clinicopathologic characteristics of the basal-like carcinomas have not been described in Egyptian (mainly in Upper Egypt) population.
In this study, we found that 81/ 147 cases (48%) were of the basal phenotytpe, this is close to results of one study done in 2010 where they found that 54% of the cases were of basal phenotype [26] , but higher than the results of another study done in 2012 where they reported that 22% of the cases were of basal phenotype [27] . Our results were in contrast to two other studies where they pointed out that 84% and 9.6% of their cases, respectively were of the basal phenotype [25, 28] . As noted, that discrepancy may originate from differences between studies in defining the basal-like subtype, since neither the definition of basal markers [29, 30] . Also, genetic, ethnic and racial factors may influence breast carcinoma molecular subtypes, possibly by determining intrinsic differences in tumor biology [4] . For this reason, it is suggested that the terminology "basal-like carcinoma" should not be used in the pathology report [30] .
Among clinicopathologic findings, we detected that basal-like tumors occurred more commonly in an older age group (58% were older than 50 years old), with no difference from non-basal breast carcinomas (NBBCs). We agreed with two studies using gene expression profile (GEP), where the average age of basal-like carcinomas was 51 and 59, respectively [4, 13] . Tumor size and lymph node metastasis are important prognostic factors for breast carcinomas. In most of the studies, it has been shown that BLBCs had larger tumor size and a tendency for visceral metastases instead of lymph node metastases [12, 14, 31, 32] .
However, others did not agree with these observations [13, 24, 33] . In this study, the size of BLBCs was mainly larger than 2 cm (85%), with no difference from NBBCs (p=0.75). Regarding lymph node metastasis, the percentage for BLBCs and NBBCs were nearly similar (74% versus 77%, respectively, p=0.27).
The typical histological appearance of BLBCs has been reported to be a circumscribed, solid lesion with pushing border and a large central and geographic necrosis or sclerosis. They have nuclear pleomorphism with high histological grade and high mitotic rate (usually more than 40-45 mitosis per 10 HPFs), consistent with their aggressive behavior [10, 21, 25, [34] [35] [36] . Other common morphological features are stromal lymphocytic response, tumor cells with high nuclear to cytoplasmic ratio, vesicular chromatin and prominent nucleoli [21, 25, [37] [38] [39] .
Most of the analyzed BLBC cases in this study were of moderate histologic grade (81.5%) but without differences from the NBBCs (p=0.22). Our findings may be due to smaller cohort study (81 cases) in comparison to the larger number in the former mentioned studies which portends even more adverse clinicopathologic associations. Also, those findings may be due to that our cases were mainly IDC-NOS and most of them were mainly grade two with few cases of special histological morphology that couldn't cover the typical morphology of BLBCs which mainly of high grade. Although central and geographic necrosis was detected in only 42% and 35% of BLBCs and NBBCs respectively in our study, this difference was statistically significant (p<0.001). Consistent with the literature [21, 37, 38, 40] , any degree of stromal lymphocytic response was the most common morphological feature for BLBCs among other clinicopathological criteria investigated in this study (more than 90%).
Our study revealed that BLBCs have infiltrative tumor margins (95%) and this finding is particularly different from most of the literatures [15, 18, 21, 27, 30, 36, 39, 41] where BLBCs were characterized by expansile (pushing) margins. This may be explained by the fact that most of our cases sought medical advices in advanced stages where the tumors were more aggressive and more invasive.
Although carcinoma in situ (CIS) is regarded as a precursor lesion for most of the invasive breast carcinomas [42] , the reported incidence of accompanying CIS in BLBCs is low [25, 34, 38, 43] .
Compatible with these data, CIS did not accompany 79% of the BLBCs in this study, supporting the idea that BLBC transforms to invasive cancer in an early stage, without remaining in pre-invasive CIS stage.
In our work, lymphovascular invasion was detected in 42% of our BLBC cases while none of the NBLBCs showed LVI, with a high significant association between both groups (P<0.001). These results were in contrast to results of two studies done by Rakha et al. (2012) and Gazinska et al. (2013) where they found that the basal group was characterized by an absence of lymphovascular invasion in comparison to the nonbasal group with a p-value< 0.001. They concluded that lymphovascular invasion was an independent prognostic factor for poor outcome in triple negative breast cancers and lymph node-negative and ERnegative breast cancers, supporting the lack of lymphovascular invasion in the basal group having a lower risk of breast cancer-specific death [21, 44] . Our findings were slightly nearer to those found by a study conducted by Mohammed et al. (2011) where they reported vascular invasion was detected in 27% of the basal-like tumors compared to 21% in the non-basallike group. Mohammed et al. (2011) found that vascular invasion, had been generally accepted, for some time, as a risk factor for development of recurrence and death from the disease. Basal-like breast cancers have been reported to show preferable metastatic dissemination to sites such as the brain and liver, and less to the bone [35, 45, 46] . These distinctive metastatic patterns have been interpreted as a distinctive ability of basal-like breast cancers for early blood-borne metastasis. It was assumed, from such observations, that the frequency of blood vascular invasion would be higher in basal-like than in the non-basal-like group [47] .
Our study did not detect any statistically significant associations between basal tumors and shorter overall survival or disease-free intervals of the patients or even patients exhibited distant metastases. These findings were in contrast to many studies which showed significant association with shorter OS and DFI especially in high grade tumors and concomitantly associated with poor outcomes [15, 28, 36, 48] .
Differences may be due to shortage of the clinical follow up data of many patients mainly because of financial and cultural problems. Also, as the treatment regimens were different, we acknowledge a diverse influence on the outcome data.
As a summary, in this study BLBCs exhibit moderate histologic grade, central and geographic necrosis, infiltrative tumor borders, lymphovascular invasion and stromal lymphocytic infiltrate. Carcinoma in situ usually does not accompany the tumor.
Study limitations include the fact that this cohort of basal-like breast cancers was relatively small, derived from consecutive cases from one hospital over a period of many years and that systemic treatments were not standardized, making outcomes stratified by treatment difficult to interpret. In addition, it is possible that some discrepancies could be attributed to the use of tissue microarrays for immunohistochemical evaluation, which cannot overcome the intratumoral heterogeneity for basal cytokeratin expression. 
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